Staphylococcus aureus resistant to the vancomycine

VRSA or SARV is Staphylococcus aureus (usually called “Staphylocoque gilded”), resistant to the Vancomycine.

It was identified in 1997 in Japan and was found since in hospitals in England, France and the United States.

The VRSA is also indicated under the terms:

  • LAY (glycopeptide intermediate Staphylococcus aureus )
  • or AIMED (vancomycin intermediate Staphylococcus aureus ), indicating a glycopeptidic resistance to all the Antibiotique S.

The SARV resists the vancomycine but is sensitive (at least for the moment) to Linézolide, a new antibiotic also covering the staphilococcus aureus resistant to the cloxacylline (SARM) and the entérocoques ones resisting vancomycine (ERV) also. This antibiotic is on the other hand very expensive (approximately 100$ per amount, 2 amounts per day in per bone). It has as possible side effect occurred of thrombophlébites thus the follow-up of the FSC is indicated.

Random links:Lists of aviators | Green-the-large | 1912 in science | Racing Antwerp Tennis shoe | Geospiza | Janv._Kavan